Nethisinghe Suran, Pigazzini Maria Lucia, Pemble Sally, Sweeney Mary G, Labrum Robyn, Manso Katarina, Moore David, Warner Jon, Davis Mary B, Giunti Paola
Ataxia Centre, Department of Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom.
Neurogenetics Unit, National Hospital for Neurology and Neurosurgery (NHNN), London, United Kingdom.
Front Cell Neurosci. 2018 Jul 31;12:200. doi: 10.3389/fncel.2018.00200. eCollection 2018.
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder caused by an expansion of a polyglutamine tract within the gene. Normal alleles have been reported to range from 6 to 35 repeats, intermediate alleles from 36 to 38 repeats and fully penetrant pathogenic alleles have at least 39 repeats. This distribution was based on relatively few samples and the narrow intermediate range makes the accuracy of the repeat sizing crucial for interpreting and reporting diagnostic tests, which can vary between laboratories. Here, we examine the distribution of 6378 SCA1 chromosomes and identify a very late onset SCA1 family with a fully penetrant uninterrupted pathogenic allele containing 38 repeats. This finding supports the theory that polyQ toxicity is related to the increase of the length of the inherited tracts and not as previously hypothesized to the structural transition occurring above a specific threshold. In addition, the threshold of toxicity shifts to a shorter polyQ length with the increase of the lifespan in SCA1. Furthermore, we show that SCA1 intermediate alleles have a different behavior compared to the other polyglutamine disorders as they do not show reduced penetrance when uninterrupted. Therefore, the pathogenic mechanism in SCA1 is distinct from other cytosine-adenine-guanine (CAG) repeat disorders. Accurately sizing repeats is paramount in precision medicine and can be challenging particularly with borderline alleles. We examined plasmids containing cloned CAG repeat tracts alongside a triplet repeat primed polymerase chain reaction (TP PCR) CAG repeat ladder to improve accuracy in repeat sizing by fragment analysis. This method accurately sizes the repeats irrespective of repeat composition or length. We also improved the model for calculating repeat length from fragment analysis sizing by fragment analyzing 100 cloned repeats of known size. Therefore, we recommend these methods for accurately sizing repeat lengths and restriction enzyme digestion to identify interruptions for interpretation of a given allele's pathogenicity.
1型脊髓小脑共济失调(SCA1)是一种常染色体显性神经退行性疾病,由该基因内多聚谷氨酰胺序列的扩增引起。据报道,正常等位基因的重复次数为6至35次,中间等位基因为36至38次,完全显性的致病等位基因至少有39次重复。这种分布是基于相对较少的样本,而狭窄的中间范围使得重复序列大小的准确性对于解释和报告诊断测试至关重要,不同实验室的测试结果可能会有所不同。在此,我们研究了6378条SCA1染色体的分布,并鉴定出一个发病非常晚的SCA1家族,其完全显性的不间断致病等位基因含有38次重复。这一发现支持了多聚谷氨酰胺毒性与遗传序列长度增加有关的理论,而不是如先前假设的那样与特定阈值以上发生的结构转变有关。此外,随着SCA1患者寿命的增加,毒性阈值会转移到较短的多聚谷氨酰胺长度。此外,我们发现SCA1中间等位基因与其他多聚谷氨酰胺疾病具有不同的行为,因为它们不间断时不会表现出降低的显性。因此,SCA1的致病机制与其他胞嘧啶 - 腺嘌呤 - 鸟嘌呤(CAG)重复疾病不同。在精准医学中,准确确定重复序列大小至关重要,尤其是对于临界等位基因,这可能具有挑战性。我们将含有克隆CAG重复序列的质粒与三联体重复引物聚合酶链反应(TP PCR)CAG重复阶梯一起进行检测,以通过片段分析提高重复序列大小测定的准确性。该方法无论重复序列的组成或长度如何,都能准确测定重复序列大小。我们还通过对100个已知大小的克隆重复序列进行片段分析,改进了从片段分析大小计算重复长度的模型。因此,我们推荐这些方法用于准确测定重复序列长度,并通过限制性酶切消化来识别中断情况,以解释给定等位基因的致病性。